Asia Pacific clinical trials market will grow by 8.2% annually with a total addressable market cap of $104,282.0 million over 2022-2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments.
Highlighted with 36 tables and 78 figures, this 142-page report “Asia Pacific Clinical Trials Market 2021-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.
Based on Product Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Trials of Drugs
o Small Molecule Drugs
o Vaccines
o Cell & Gene Therapy
o Other Drugs
• Trials of Devices
• Trials of Procedures
Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Phase I
• Phase II
• Phase III
• Phase IV
By Design, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Interventional Studies
o Randomized Control Trial
o Adaptive Clinical Trial
o Non-randomized Control Trial
• Observational Studies
o Cohort Study
o Case Control Study
o Cross Sectional Study
o Ecological Study
• Expanded Access Trials
By Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Clinical Trial Supply & Logistic Services
• Decentralized Clinical Trial Services
• Medical Device Testing Services
• Other Clinical Trial Services
By Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Oncology
• Infectious Diseases
• Cardiology
• Obesity
• Diabetes
• Neurology
• Immunology
• Pain Management
• Other Indications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharmaceutical and Biotechnological Companies
• Clinical Research Organizations
• Clinical Testing Laboratories
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Phase, Design, and Indication over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Accell Clinical Research LLC
Charles River Laboratory
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PRA Health Sciences
Sanofi SA
SGS SA
Syneos Health Inc.
Wuxi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Asia Pacific Market by Product Category 43
3.1 Market Overview by Product Category 43
3.2 Trials of Drugs 45
3.2.1 Small Molecule Drugs 46
3.2.2 Vaccines 47
3.2.3 Cell & Gene Therapy 48
3.2.4 Other Drugs 49
3.3 Trials of Devices 50
3.4 Trials of Procedures 51
4 Segmentation of Asia Pacific Market by Phase 52
4.1 Market Overview by Phase 52
4.2 Phase I 54
4.3 Phase II 55
4.4 Phase III 56
4.5 Phase IV 57
5 Segmentation of Asia Pacific Market by Design 58
5.1 Market Overview by Design 58
5.2 Interventional Studies 60
5.2.1 Randomized Control Trial 62
5.2.2 Adaptive Clinical Trial 63
5.2.3 Non-randomized Control Trial 64
5.3 Observational Studies 65
5.3.1 Cohort Study 67
5.3.2 Case Control Study 68
5.3.3 Cross Sectional Study 69
5.3.4 Ecological Study 70
5.4 Expanded Access Trials 71
6 Segmentation of Asia Pacific Market by Service Type 72
6.1 Market Overview by Service Type 72
6.2 Protocol Designing 74
6.3 Site Identification 75
6.4 Patient Recruitment 76
6.5 Laboratory Services 77
6.6 Bioanalytical Testing Services 78
6.7 Clinical Trial Data Management Services 79
6.8 Clinical Trial Supply & Logistic Services 80
6.9 Decentralized Clinical Trial Services 81
6.10 Medical Device Testing Services 82
6.11 Other Clinical Trial Services 83
7 Segmentation of Asia Pacific Market by Indication 84
7.1 Market Overview by Indication 84
7.2 Oncology 86
7.3 Infectious Diseases 87
7.4 Cardiology 88
7.5 Obesity 89
7.6 Diabetes 90
7.7 Neurology 91
7.8 Immunology 92
7.9 Pain Management 93
7.10 Other Indications 94
8 Segmentation of Asia Pacific Market by End User 95
8.1 Market Overview by End User 95
8.2 Pharmaceutical and Biotechnological Companies 97
8.3 Clinical Research Organizations 98
8.4 Clinical Testing Laboratories 99
8.5 Other End Users 100
9 Asia-Pacific Market 2021-2031 by Country 101
9.1 Overview of Asia-Pacific Market 101
9.2 Japan 104
9.3 China 107
9.4 Australia 110
9.5 India 112
9.6 South Korea 114
9.7 Rest of APAC Region 116
10 Competitive Landscape 118
10.1 Overview of Key Vendors 118
10.2 New Product Launch, Partnership, Investment, and M&A 122
10.3 Company Profiles 123
Accell Clinical Research LLC 123
Charles River Laboratory 125
ClinDatrix Inc 126
Clinipace 127
Eli Lilly and Company 128
F. Hoffmann-La Roche Ltd. 129
ICON PLC 130
IQVIA Holdings, Inc. 131
Laboratory Corporation of America 132
Novo Nordisk AS 133
PAREXEL International Corporation 134
Pfizer Inc. 135
Pharmaceutical Product Development LLC 136
PRA Health Sciences 137
Sanofi SA 138
SGS SA 139
Syneos Health Inc. 140
Wuxi AppTec Inc. 141
RELATED REPORTS 142
Selected Key Players:
Accell Clinical Research LLC
Charles River Laboratory
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PRA Health Sciences
Sanofi SA
SGS SA
Syneos Health Inc.
Wuxi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Ěý
Ěý
*If Applicable.
